KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Interest Expenses (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Interest Expenses for 8 consecutive years, with $14.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 42.19% year-over-year to $14.1 million, compared with a TTM value of $78.9 million through Dec 2025, down 19.94%, and an annual FY2025 reading of $78.9 million, down 19.94% over the prior year.
  • Interest Expenses was $14.1 million for Q4 2025 at Biocryst Pharmaceuticals, down from $19.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $104.4 million in Q4 2023 and bottomed at $14.1 million in Q4 2025.
  • Average Interest Expenses over 3 years is $31.3 million, with a median of $24.4 million recorded in 2024.
  • The sharpest move saw Interest Expenses plummeted 76.58% in 2024, then fell 4.13% in 2025.
  • Year by year, Interest Expenses stood at $104.4 million in 2023, then tumbled by 76.58% to $24.4 million in 2024, then plummeted by 42.19% to $14.1 million in 2025.
  • Business Quant data shows Interest Expenses for BCRX at $14.1 million in Q4 2025, $19.7 million in Q3 2025, and $21.6 million in Q2 2025.